peppersite
Metabolic supportsubcutaneous

MOTS-c

MOTS-c is a short chain of 16 amino acids that cells build from mitochondrial DNA rather than from the DNA in the nucleus. Most of what is known about it comes from cell and animal work on metabolism, exercise capacity and insulin sensitivity.

Researched for
Metabolic HealthLongevityPerformance RecoveryRecovery

At a glance

Type
Metabolic support
Given by
subcutaneous
Evidence
AnimalAnimal, across 1 audit
Reported amount
5 mg per Peptide Dosing Protocols. All 4 sources
Typical vial
10 mg in 1 mL

How much to draw

Full calculator →
Your draw
50units
0.5 mL on a U-100 insulin syringe
10 mg/mL2 doses per vial
Vial size:
Amount per dose

Opened on 5 mg, the figure Peptide Dosing Protocols reports for MOTS-c, and a 10 mg vial in 1 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for MOTS-c or for anything else, and nothing below has been checked against the study it came from.

5-10 mg SC 2-3 times weekly
Frequency
2-3 times weekly4 weeks · 4-week cycles
Route
subcutaneous
Reported by
Commonly published practitioner dosing range - provider confirmation required.
5-10 mg per injection
Frequency
2-3 times per week or every 5 days
Route
subcutaneous
Reported by
Peptide Protocol Wiki
Standard: 5 mg · Low: 5 mg · High: 10 mg
Frequency
2 to 3 times per week4 to 8 weeks · 4-6 weeks
Route
Subcutaneous injection
Reported by
Peptide Dosing Protocols
What it saysThe standard dosing is 5 mg subcutaneously, 3 times per week for 4-6 weeks.
Referenced at 10 mg weekly in divided doses within longevity stacking. Morning administration cited for circadian and mitochondrial alignment.
Frequency
Weekly total (10 mg), divided doses · MorningCycle every few months in longevity contexts
Route
subcutaneous
Reported by
Peptide Therapy Reference Text
What it saysAug 2026), secondary reference; provider confirmation required.
Reconstitution, as reported
  • Commonly 10 mg vials · Reconstitute with bacteriostatic water
  • Bacteriostatic water
  • Reconstitute a 10 mg vial with 1.0 mL bacteriostatic water
What our audits found

How it is thought to work

The body makes more MOTS-c during exercise and physical stress, and levels fall with age. It appears to push cells to take in more glucose, burn more fat and build more mitochondria over time. Researchers link this to activation of AMPK, an enzyme that acts as a cellular energy switch. No published human randomized trial has tested native MOTS-c for any clinical endpoint.

In technical termsMitochondrial and metabolic signaling.

What we don't know

Whether it works in people: no published human randomized controlled trial has tested native MOTS-c for any clinical endpoint. The running-capacity effect seen in mice has not been reproduced in a human randomized trial.

What the human data show: the human findings are links between blood levels of MOTS-c and measures such as muscle strength or markers in kidney failure. They do not show what happens when MOTS-c is given to a person.

Safety: the closest randomized human safety data is for CB4211, a related but different molecule, so that result does not carry over fully.

Cancer: findings on tumour biology are mixed, and the direction of the effect is described as not settled.

Reported side effects

Seen in studies: a synthetic relative of MOTS-c called CB4211 completed an early-phase human trial reported as safe and well tolerated. That is a similar but different molecule, so the finding does not carry over fully.

Reported by users: redness or swelling where it is injected is described as common. Flushing or warm skin, headache and mild tiredness are described as occasional. The U.S. Anti-Doping Agency also lists heart palpitations, insomnia and fever. None of these come from a randomized human trial.

Not ruled out: the effect on cancer is unsettled, with some animal work showing MOTS-c slowing certain tumour lines and other sources flagging possible risk in prostate and breast cancer. Research-grade material can carry impurities, and an unwanted immune reaction is listed as a risk in regulatory material on protein-based products.

Who should avoid it

People with an active cancer diagnosis: the effect on tumour biology is mixed, with slowing of some tumour lines in animals and flagged risk in other settings, and the direction is described as not settled.

People who are pregnant or breastfeeding: there is no human safety data.

People taking other AMPK-activating drugs such as metformin, thiazolidinediones or aspirin: the overlap in AMPK activation has an unknown net effect.

Athletes tested under WADA rules: MOTS-c is prohibited at all times under section S4.4.1.

Anyone who would not have access to a clinician if a side effect appeared: listed as a caution in the reference library, with no reason given.

What gets monitored

Waist circumference, bodyweight trend, fasting glucose if available at weeks 4-6; subjective energy notes and sleep timing at weeks 1-2; workout logs and recovery feel at weeks 3-4. (reported by Peptide Dosing Protocols)

Regulatory status

FDA approval: none of the studied uses of MOTS-c has been approved by the FDA.

Compounding: on July 23, 2026 the FDA's Pharmacy Compounding Advisory Committee voted 7 to 5, with two abstentions, to recommend adding MOTS-c to the list of substances pharmacies may compound. The vote is advisory and does not bind the FDA. Adding a substance to the list needs formal FDA rulemaking, and news reports from July 23 and 24, 2026 said the FDA had made no final decision. FDA staff scientists had objected, citing a lack of safety and effectiveness data. None of this is FDA approval of MOTS-c as a drug.

Sport: the reference entry says MOTS-c is prohibited at all times under World Anti-Doping Agency section S4.4.1.

Checked: November 2026.

Common questions

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA rather than by the DNA in the cell nucleus. It activates AMPK, an enzyme that controls how cells use energy.

What is MOTS-c commonly researched for?

Research covers metabolic health, exercise capacity, body composition, aging, bone metabolism and inflammation. Most of that work is in cells and animals, and direct human evidence is limited.

How is MOTS-c commonly described in research planning?

Reported amounts and schedules for MOTS-c differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

What do sources report as a standard MOTS-c dosage chart?

Reported amounts and schedules for MOTS-c differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

How is MOTS-c reconstituted?

That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.

How long is a typical MOTS-c cycle?

Reported amounts and schedules for MOTS-c differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

What are the main side effects of MOTS-c?

Reported effects include redness or swelling at the injection site, flushing, mild tiredness and headache. These come from user reports and clinician sources rather than from a randomized human trial.

Why does MOTS-c sometimes cause flushing?

Sources describe MOTS-c triggering mast cell activation, which releases histamine. That can produce warmth, redness or itching.

Sources

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things
Glutathione

Glutathione (GSH) is a small molecule built from three amino acids, cysteine, glycine and glutamate, made by nearly every cell and most of all by the liver. It has been studied in people for skin lightening, liver enzymes in fatty liver disease, and Parkinson's disease.

Sermorelin Acetate

Sermorelin is a lab-made peptide that copies the first 29 amino acids of the body's own growth hormone-releasing hormone (GHRH). It has been studied in the growth hormone system, including FDA-era trials as a diagnostic agent and as a treatment for growth hormone deficiency in children.

Tesamorelin / Ipamorelin

This is a combination of two growth hormone compounds sold in a single vial: tesamorelin, a synthetic copy of growth hormone-releasing hormone, and ipamorelin, a ghrelin mimic that acts as a growth hormone secretagogue. It is sold for research use and is studied in the context of the growth hormone system, visceral fat and recovery.

GHK-Cu

GHK-Cu, or copper tripeptide-1, is a natural peptide of three amino acids bound to a copper ion, found in human blood plasma. It is studied for skin, hair and wound repair, mostly in cells and animals, with the strongest human evidence for topical use.

5-Amino-1MQ

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.

BPC-157

BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.